Abstract
Background: worldwide, prostate cancer is the second most common cancer and the fifth leading cause of death from cancer in men.
Objective: studying the impact of hormonal treatment in patients with metastatic prostatic carcinoma.
Subjects and Methods: This retrospective study included all patients diagnosed with metastatic prostate cancer, treated at our center between the year 2007 and 2016, data of patients included was reviewed from the charts and analyzed for outcome.
Results: the study included 39 patients, 21 patients (52.6 %) had subjected to primary bilateral orchiectomy as first line management while (18) patients (47.4%) received ADT. Median PFS for 1st line hormonal treatment was18.4 months and Median OS were 25.5 months. Patients with good performance (PS) status 0- II had longer overall survival than those with PS III (37 vs. 18 months) with significant P- value (0.05).Patients with base line PSA around 70ng/ml had longer OS (23 vs. 11 months) with significant P- value (0.05).
Conclusions: Outcome of metastatic prostate cancer patients who have been treated at our center significantly affected by PS at presentation and baseline PSA level, however the absolute survival number needs to be improved by implementation of newly approved drugs in the 1st and 2nd lines, that isn't currently available in our center.